Non-Small Cell Lung Cancer

Showing 1 - 25 of 1,271

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Trial in Changsha (Time of immunotherapy infusion)

Recruiting
  • Non-small Cell Lung Cancer
  • Time of immunotherapy infusion
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 24, 2022

NSCLC Trial (QLH11811)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Sep 22, 2022

NSCLC Trial in Changsha, Shanghai, Hangzhou (H002 capsule)

Recruiting
  • Non-small Cell Lung Cancer
  • H002 capsule
  • Changsha, Hunan, China
  • +2 more
Sep 20, 2022

NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Furmonertinib 160 mg, Q.D.
  • Chongqing, Chongqing, China
  • +2 more
Sep 16, 2022

NSCLC Trial in China (Osimertinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Beijing, China
  • +3 more
Sep 15, 2022

NSCLC, Pancreatic Cancer, Colorectal Cancer Trial in San Antonio, Wenatchee (ponsegromab, Placebo for ponsegromab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +5 more
  • San Antonio, Texas
  • +1 more
Sep 15, 2022

NSCLC Trial

Not yet recruiting
  • Non-small Cell Lung Cancer
    • (no location specified)
    Sep 14, 2022

    Advanced Solid Tumors, NSCLC Trial in Hackensack (BMS-986442, Nivolumab, Docetaxel)

    Not yet recruiting
    • Advanced Solid Tumors
    • Non-small Cell Lung Cancer
    • BMS-986442
    • +5 more
    • Hackensack, New Jersey
      John Theurer Cancer Center at Hackensack University Medical Cent
    Sep 14, 2022

    PLAsma Genomic Testing in Advanced Non-Small Cell Lung Cancer:

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • ctDNA liquid biopsy - Roche Avenio Assay
    • (no location specified)
    Sep 14, 2022

    NSCLC Trial (Almonertinib Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Almonertinib Envafolimab
    • (no location specified)
    Sep 10, 2022

    Melanoma, Glioma, Thyroid Cancer Trial (PF-07799544, PF-07284890, PF-07799933)

    Not yet recruiting
    • Melanoma
    • +6 more
    • (no location specified)
    Sep 9, 2022

    Endocrine/Neuroendocrine, NSCLC, Breast Cancer Trial run by the National Cancer Institute (NCI) (Fludarabine, Cyclophosphamide,

    Recruiting
    • Endocrine/Neuroendocrine
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 24, 2022

    Nintedanib in Indian Non-small Cell Lung Cancer After First-line

    Recruiting
    • Non-small Cell Lung Cancer
      • Anand, India
      • +11 more
      Aug 23, 2022

      Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

      Recruiting
      • Breast Cancer
      • +15 more
      • Goodyear, Arizona
      • +146 more
      Aug 24, 2022

      Harvesting Cells for Experimental Cancer Treatments

      Enrolling by invitation
      • Melanoma
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Aug 24, 2022

        NSCLC Trial (Icotinib)

        Not yet recruiting
        • Non-Small Cell Lung Cancer
        • (no location specified)
        Aug 23, 2022

        NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

        Completed
        • Non-small Cell Lung Cancer
        • Beijing, China
        • +43 more
        Aug 22, 2022

        NSCLC, Recurrent NSCLC, Metastatic NSCLC Trial in Worldwide (Nivolumab, Relatlimab, Carboplatin)

        Recruiting
        • Non-small Cell Lung Cancer
        • +2 more
        • Nivolumab
        • +6 more
        • Arcadia, California
        • +148 more
        Aug 20, 2022

        NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

        Terminated
        • Non-small Cell Lung Cancer
        • +2 more
        • Brussels, Belgium
        • +18 more
        Aug 23, 2022

        NSCLC, Stage IV, Oligometastasis Trial in Netherlands, Spain, Switzerland (drug, radiation, procedure)

        Active, not recruiting
        • Non-small Cell Lung Cancer
        • +2 more
        • Maastricht, Netherlands
        • +10 more
        Aug 23, 2022

        Atezolizumab Under Real-World Conditions in Patients Treated in

        Recruiting
        • Urothelial Carcinoma
        • +3 more
        • Buenos Aires, Argentina
        • +314 more
        Aug 22, 2022

        NSCLC Trial in Worldwide (Durvalumab)

        Recruiting
        • Non-small Cell Lung Cancer
        • Tucson, Arizona
        • +52 more
        Aug 19, 2022

        Solid Tumors, Metastatic Melanoma, NSCLC Trial in Worldwide (RO7247669)

        Recruiting
        • Solid Tumors
        • +3 more
        • San Diego, California
        • +20 more
        Aug 19, 2022

        NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

        Recruiting
        • Non-Small Cell Lung Cancer
        • Berazategui, Buenos Aires, Argentina
        • +205 more
        Aug 17, 2022

        NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

        Active, not recruiting
        • Non-small Cell Lung Cancer
        • Pembrolizumab
        • +4 more
        • Shanghai, China
          Zhongshan Hospital Fudan University
        Aug 18, 2022